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The CCND1 gene, a key cell-cycle regulator, is often altered in breast cancer, but the mechanisms underlying CCND1
dysregulation and the clinical signiﬁcance of CCND1 status are unclear. We used real-time quantitative PCR and RT–PCR
assays based on ﬂuorescent TaqMan methodology to quantify CCND1 gene ampliﬁcation and expression in a large series of
breast tumours. CCND1 overexpression was observed in 44 (32.8%) of 134 breast tumour RNAs, ranging from 3.3 to 43.7
times the level in normal breast tissues, and correlated signiﬁcantly with positive oestrogen receptor status (P=0.0003).
CCND1 overexpression requires oestrogen receptor integrity and is exacerbated by ampliﬁcation at 11q13 (the site of the
CCND1 gene), owing to an additional gene dosage effect. Our results challenge CCND1 gene as the main 11q13 amplicon
selector. The relapse-free survival time of patients with CCND1-ampliﬁed tumours was shorter than that of patients without
CCND1 alterations, while that of patients with CCND1-unampliﬁed-overexpressed tumours was longer (P=0.011). Only the
good prognostic signiﬁcance of CCND1-unampliﬁed-overexpression status persisted in Cox multivariate regression analysis.
This study conﬁrms that CCND1 is an ER-responsive or ER-coactivator gene in breast cancer, and points to the CCND1 gene
as a putative molecular marker predictive of hormone responsiveness in breast cancer. Moreover, CCND1 ampliﬁcation status
dichotomizes the CCND1-overexpressing tumors into two groups with opposite outcomes.
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Cyclin D1, a protein encoded by the CCND1 gene, has a well-
established role in regulating progression through the G1 phase
of the cell cycle. Cyclin D1 acts by complexing with the cyclin-
dependent kinases CDK4 and CDK6, promoting phosphorylation
and inactivation of retinoblastoma protein. CCND1 has been iden-
tiﬁed as an oncogene, and is rearranged, ampliﬁed or overexpressed
in a variety of tumours (Motokura and Arnold, 1993). Recent
results from several groups suggest that cyclin D1 may also be
involved in the activities of transcription factors through CDK-
independent mechanisms. Cyclin D1 can bind to and regulate
the activity of several proteins, including myb-like transcription
factor (DMP1) (Inoue and Sherr, 1998), the myogenic transcrip-
tion factor MyoD (Skapek et al, 1996), and also the oestrogen
receptor, through the recruitment of p300/CBP-associated protein
(P/CAF) and steroid receptor coactivator-1 (SRC-1) (Zwijsen et
al, 1997, 1998; Neuman et al, 1997; McMahon et al, 1999).
Cyclin D1 aberrations have been strongly linked to human
breast cancer. Ectopic expression of cyclin D1 is sufﬁcient to initi-
ate cell cycle progression in the absence of external growth stimuli
(Musgrove et al, 1994). Transgenic mice carrying the CCND1 gene
driven by the mouse mammary tumour virus terminal repeat show
altered mammary cell proliferation and a high incidence of
mammary adenocarcinomas (Wang et al, 1994). Clinical studies
have found ampliﬁcation of 11q13 chromosomal region (which
contains CCND1) in 10–15% of human primary breast cancers
(Ali et al, 1989; Borg et al, 1991; Schuuring et al, 1992; Henry et
al, 1993). However, overexpression (at both the mRNA and protein
levels) is seen in about 50% of cases, suggesting that mechanisms
other than DNA ampliﬁcation may dysregulate cyclin D1 expres-
sion (McIntosh et al, 1995; Gillett et al, 1996; Barbareschi et al,
1997; Jares et al, 1997; Nielsen et al, 1997; Kenny et al, 1999). It
is noteworthy that it has been previously described a high correla-
tion between overexpression of CCND1 mRNA and increased
presence of Cyclin D1 protein (Bartkova et al, 1994; Gillett et al,
1994).
The regulation of CCND1 gene expression is poorly understood.
Experimental data show that cyclin D1 expression can be regulated
by several factors which may be dysregulated in breast cancer,
including growth factors (Musgrove et al, 1993), p53 through
p21WAF1 (Chen et al, 1995) and oestrogen (Musgrove et al,
1994; Altucci et al, 1996). It is noteworthy that most CCND1-over-
expressing tumours are oestrogen receptor-positive (Hui et al,
1996; Barbareschi et al, 1997; Jares et al, 1997). Finally, cyclin D1
is frequently overexpressed in ductal carcinoma in situ, and also
in some benign breast diseases (Weinstat-Saslow et al, 1995; Alle
et al, 1998), pointing to a role in the earliest stages of breast
tumour development.
The action of cyclin D1 in cell cycle control, its role in
murine mammary gland development and oncogenesis, its altered
expression in half of all human breast tumours and in the
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vement in the action of oestrogen, have led to numerous studies
to ascertain whether cyclin D1 may serve as a biological marker
in breast cancer. However, clinical studies have produced unex-
pected results. Indeed, CCND1 ampliﬁcation has been linked to
poor outcome (Ali et al, 1989; Borg et al, 1991; Schuuring et
al, 1992; Henry et al, 1993), whereas overexpression of cyclin
D1, as determined by immunohistochemical methods, has been
linked to good outcome (Gillett et al, 1996). The latter associa-
tion could be explained by a link between cyclin D1
overexpression and well-differentiated, ER-positive carcinomas,
which carry a better prognosis. In this regard, we recently
suggested in a small series of breast tumors (n=33) that CCND1
mRNA overexpression is related to oestrogen receptor positively
(Spyratos et al, 2000).
CCND1 expression status might also be a useful marker to
predict the response to endocrine therapy (Gillett et al, 1996;
Sutherland et al, 1997; Wilcken et al, 1997; Barnes and Gillett,
1998).
Finally, CCND1 appears to be an outstanding candidate thera-
peutic target, and several studies have shown that antisense to
CCND1 inhibits the growth and reverses the transformed pheno-
type of human cancer cells (Zhou et al, 1995; Arber et al, 1997).
These promising clinical perspectives call for a sensitive, accurate
and rapid method to screen breast cancer patients for CCND1
ampliﬁcation/overexpression. We developed a real-time quantita-
tive RT–PCR assay based on TaqMan methodology to quantify
CCND1 mRNA in homogeneous total RNA solutions obtained
from tumour samples (Gibson et al, 1996). This method has excel-
lent performance, accuracy and sensitivity, together with a wide
dynamic range, a high throughput capacity and good interlabora-
tory agreement. In addition, it eliminates the need for tedious
post-PCR processing.
To determine the prognostic value of CCND1 ampliﬁcation and/
or overexpression, we used this real-time PCR method to measure
CCND1 gene expression at the mRNA level in a large series of
unilateral invasive primary breast tumours (n=134) with known
CCND1 gene status (Bie `che et al, 1998) and available long-term
outcome data.
As several studies have pointed to cooperation between the
CCND1 and RB1 genes, and to their joint involvement in the
proliferative capacity of tumour cells, we also sought a possible link
between CCND1 DNA and/or mRNA status and RB1 mRNA
underexpression.
MATERIALS AND METHODS
Patients and samples
We analyzed tissue from excised primary breast tumours of 134
women treated at the Centre Rene ￿ Huguenin from 1977 to 1989.
The samples were examined histologically for the presence of
tumour cells. A tumour sample was considered suitable for this
study if the proportion of tumour cells was more than 60%. Imme-
diately following surgery the tumour samples were stored in liquid
nitrogen until RNA extraction.
The patients (mean age 58.3 years, range 34–91) met the
following criteria: primary unilateral non metastatic breast carcino-
ma on which complete clinical, histological and biological data
were available; and no radiotherapy or chemotherapy before
surgery. The main prognostic factors are presented in Table 1.
The median follow-up was 8.8 years (range 1.0–16.2). Forty-eight
patients relapsed (the distribution of ﬁrst relapse events was as
follows: 14 local and/or regional recurrences, 30 metastases and
four both).
Specimens of adjacent normal breast tissue from 10 of the breast
cancer patients, and normal breast tissue from 10 women under-
going cosmetic breast surgery were used as sources of normal RNA.
Real-time RT–PCR
Theoretical basis Reactions are characterized by the point
during cycling when ampliﬁcation of the PCR product is ﬁrst
detected, rather than the amount of PCR product accumulated
after a ﬁxed number of cycles. The higher the starting quantity
of the target molecule, the earlier a signiﬁcant increase in ﬂuores-
cence is observed. The parameter Ct (threshold cycle) is deﬁned as
the fractional cycle number at which the ﬂuorescence generated by
cleavage of the probe passes a ﬁxed threshold above baseline. The
CCND1 target message in unknown samples is quantiﬁed by
measuring Ct and by using a standard curve to determine the start-
ing target message quantity.
The precise amount of total RNA added to each reaction mix
(based on optical density) and its quality (i.e. lack of extensive
degradation) are both difﬁcult to assess. We therefore also quanti-
ﬁed transcripts of the gene coding for the TATA box-binding
protein (TBP) (a component of the DNA-binding protein complex
TFIID) as the endogeneous RNA control, and each sample was
normalized on the basis of its TBP content.
For each experimental sample the amount of the targets and
endogeneous reference is determined from the standard curve.
Then, the target amount is divided by the endogeneous reference
amount to obtain a normalized target value. The relative gene
target expression level was also normalized to a normal breast
tissue sample (calibrator), or 16sample. Each of the normalized
target values is divided by the calibrator normalized target value
to generate the ﬁnal relative expression levels.
Final results, expressed as N-fold differences in CCND1 gene
expression relative to the TBP gene and the calibrator, termed
‘NCCND1’, was determined as follows:
NCCND1 
CCND1SAMPLE
TBPSAMPLE
=
CCND1CALIBRATOR
TBPCALIBRATOR
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Table 1 Charecteristics of the 134 patients and relation to relapse-free
survival
Relapse-free survival
Number of Number of
patients (%) events
a P-value
b
Age NS
450 years 41 (30.6) 12
450 years 93 (69.4) 36
Menopausal status NS
Premenopausal 47 (35.1) 16
Post-menopausal 87 (64.9) 32
Histological grade
c,d NS
I+II 78 (62.4) 30
III 47 (37.6) 17
Lymph node status 0.024
Node-negative 50 (37.3) 10
Node-positive 84 (62.7) 38
ER status NS
+(510 fm per mg) 92 (68.7) 36
7(510 fm per mg) 42 (31.3) 12
PR status NS
+(510 fm per mg) 79 (59.0) 28
7(510 fm per mg) 55 (41.0) 20
Macroscopic tumour size
e NS
430 mm 93 (73.2) 33
430 mm 34 (26.8) 13
aFirst relapses (local and/or regional recuurrences, and/or metastases);
bLog-rank test;
cScarff Bloom Richardson classiﬁcation;
dInformation available for 125 patients;
eInformation available for 127 patients.
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the TBP and CCND1 genes were chosen with the assistance of the
computer programs Oligo 4.0 (National Biosciences, Plymouth,
MN, USA) and Primer Express (Perkin-Elmer Applied Biosystems,
Foster City, CA, USA). The primer pairs for CCND1 were selected
to be unique when compared with the sequences of the closely
related CCND2 and CCND3 genes, and CCND2PS and CCND3PS
pseudogenes. The nucleotide sequences of the oligonucleotide
hybridization probes and primers are shown in Table 2. Primers
and Probes are designated by the nucleotide position (relative to
TBP GenBank Number X54993 and CCND1 GenBank Number
X59798) corresponding to the 5' position, followed by the letter
U for upper (sense strand) or L for lower (antisense strand). To
avoid ampliﬁcation of contaminating genomic DNA, one of the
two primers or the probe was placed at the junction between
two exons, or in a different exon. For example, the upper primer
of TBP (706U) was placed in exon 5, the probe (745U) at the junc-
tion between exon 5 and exon 6, and the lower primer (794L) were
placed in exon 6.
RNA extraction Total RNA was extracted from breast specimens
by using the acid-phenol guanidium method (Chomczynski and
Sacchi, 1987). The quality of the RNA samples was determined
by electrophoresis through denaturing agarose gels and staining
with ethidium bromide, and the 18S and 28S RNA bands were
visualized under ultraviolet light.
Standard curve construction The relative kinetic method was
applied using a standard curve. The latter was constructed with
four-fold serial dilutions of total RNA from normal human breast
tissues in mouse total RNA (Clontech, Category Number 64042-1).
The standard curve used for reverse transcription is composed of
ﬁve points (1000, 250, 62.5, 15.6 and 3.9 ng of human normal
breast total RNA). The series of diluted human total RNAs was
aliquoted and stored at 7808C until use.
cDNA synthesis Reverse transcription of RNA was done in a
ﬁnal volume of 20 ml containing 16 RT–PCR buffer (500 mM
each dNTP, 3 mM MgCl2,7 5m M KCl, 50 mM Tris-HCl pH 8.3),
10 units of RNasin
TM Ribonuclease inhibitor (Promega, Madison,
WI, USA), 10 mM dithiothreitol, 50 units of Superscript II RNase
H
- reverse transcriptase (Gibco–BRL, Gaithersburg, MD, USA),
1.5 mM random hexamers (Pharmacia, Uppsala, Sweden) and
1 mg of total RNA (standard curve point samples and patients’
samples). The samples were incubated at 208C for 10 min and
428C for 30 min, and reverse transcriptase was inactivated by heat-
ing at 998C for 5 min and cooling at 58C for 5 min.
PCR ampliﬁcation All PCR reactions were performed using a
ABI Prism 7700 Sequence Detection System (Perkin-Elmer Applied
Biosystems). For each PCR run a master mix was prepared on ice
with 16TaqMan buffer, 5 mM MgCl2, 200 mM dATP, dCTP and
dGTP and 400 mM dUTP, 300 nM each primer, 150 nM probe
and 1.25 units of AmpliTaq Gold DNA polymerase (Perkin-Elmer
Applied Biosystems). Ten microliters of each appropriate diluted
RT sample (standard curve points and patients’ samples) was
added to 40 ml of the PCR master-mix. The thermal cycling condi-
tions comprised an initial denaturation step at 958C for 10 min
and 50 cycles at 958C for 15 s and 658C for 1 min.
Experiments were performed with duplicates for each data point.
All the patients’ samples with a CV of the number of TBP or
CCND1 mRNA copies higher than 10% were retested.
Statistical analysis
Relapse-free survival (RFS) was determined as the interval between
diagnosis and detection of the ﬁrst relapse (local and/or regional
recurrences, and/or metastases). Clinical, histological and biological
parameters were compared using the chi-square test. Differences
between the two populations were judged signiﬁcant at conﬁdence
levels greater than 95% (P50.05). Survival distributions were esti-
mated by the Kaplan–Meier method (Kaplan and Meier, 1958),
and the signiﬁcance of differences between survival rates was ascer-
tained using the log-rank test. Multivariate analysis using Cox’s
proportional hazards model (Cox, 1972) was used to assess the
independent contribution of each variable to RFS.
RESULTS
Validation of the standard curve and dynamic range of
real-time RT–PCR
The dynamic range of the CCND1 real-time RT–PCR assay was
wide (at least three orders of magnitude) with samples containing
as much as 50 ng or as little as 0.2 ng equivalent total cDNA. A
strong linear relationship between the Ct and the log of starting
copy number was always demonstrated (R
250.99). The efﬁciency
of the reaction (E), calculated by the formula: E=10
1/|m|71, where
m is the slope of standard curve line, was ranged from 90 to 100%
for the different assays. All breast tissue samples which were
analyzed consistently fell within the calibration curve.
CCND1 mRNA level in normal breast tissues
To determine the cut-off point for altered CCND1 gene expression
at the RNA level in breast cancer tissue, the NCCND1 value, calcu-
lated as described in Materials and methods, was determined for 20
normal breast tissue RNAs. As this value consistently fell between
0.6 and 1.8 (mean 1.03+0.37 standard deviation), values of three
(mean+5 s.d.) or more were considered to re¯ect overexpres-
sion of the CCND1 gene in tumour RNA samples.
CCND1 mRNA level in breast tumour tissues
Among the 134 breast tumour RNA samples tested, 44 (32.8%)
showed CCND1 overexpression. Major differences in the amount
of CCND1 mRNA were observed (NCCND1 from 3.3 to 43.7); 19
tumours (14.2%) had an expression level three to ﬁve times higher
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s
Table 2 Oligonucleotide primer and probe sequences used
PCR
product
Genes Oligonucleotide Location Sequence size (pb)
CCND1 Upper primer 335U 5'-GGATGCTGGAGGTCTGCGA-3'
Lower primer 480L 5'-AGAGGCCACGAACATGCAAG-3' 146
Probe 371U 5'-AGGAGGTCTTCCCGCTGGCCATGAAC-3'
TBP Upper primer 706U 5'-CACGAACCACGGCACTGATT-3'
Lower primer 794L 5'-TTTTCTTGCTGCCAGTCTGGAC-3' 89
Probe 745U 5'-TGTGCACAGGAGCCAAGAGTGAAGA-3'
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contained amounts ﬁve to 10 times higher, six tumours (4.5%)
10 to 20 times higher, and four tumours (3.0%) more than 20
times higher. Among the 10 patients in whom both the primary
breast tumour and matched normal breast tissue were investigated,
CCND1 expression was far higher in three tumours than in the
normal tissue (NCCND1=8.1, 4.8 and 3.6, compared to 0.9, 1.2
and 0.2, respectively).
Relationship between the CCND1 RNA levels and CCND1
ampliﬁcation levels
All 134 tumours studied for CCND1 expression at the RNA level
had previously been tested for CCND1 ampliﬁcation by Southern
blot analysis (unpublished data), and 94 had also been tested
(when DNA was still available) with a real-time quantitative PCR
assay based on TaqMan technology (Bie `che et al, 1998). As the
TaqMan technology was more sensitive than Southern blotting
(Bie `che et al, 1998), we increased the cut-off for gene ampliﬁcation
in the real-time PCR assay from two to 2.5 to have a total correla-
tion between this latter method and Southern blot analysis. With
the new cut-off, 15 (11.2%) of the 134 tumours tested here showed
CCND1 ampliﬁcation. CCND1 overexpression was found in all but
three of the tumours that showed 11q13 ampliﬁcation (Table 3).
The CCND1 mRNA and DNA status of these three tumours was
conﬁrmed by conducting a second RNA and DNA extraction, by
additional real-time quantitative PCR and RT–PCR analyses (use
of new primer pairs for the CCND1 and TBP genes, and an addi-
tional endogeneous RNA control; the RPLP0 gene (also known as
36B4) encoding human acidic ribosomal phosphoprotein P0) and
by Northern and Southern analysis.
Interestingly, the CCND1-ampliﬁed-overexpressed tumours
contained larger amounts of CCND1 mRNA (12 tumours; mean
NCCND1 17.9, range 7.6 to 43.7) than did the CCND1-unampli-
ﬁed-overexpressed tumours (32 tumours; mean NCCND1 5.6;
range 3.3 to 8.6).
Correlation between CCND1 mRNA and DNA status and
clinical, pathological and biological parameters
We sought links between CCND1 mRNA and DNA status (altera-
tion versus normal) and standard clinical, pathological and
biological factors in breast cancer (Table 4). Patients with
CCND1-altered tumours (n=47) were subdivided into those with
CCND1-ampliﬁed tumours (n=15) and those with CCND1-unam-
pliﬁed-overexpressed tumours (n=32).
The only statistically signiﬁcant link was between CCND1-
unampliﬁed-overexpressed tumours and oestrogen receptor posi-
tivity (P=0.0003). Only one (3.1%) of the 32 patients with
CCND1-unampliﬁed-overexpressed tumours was oestrogen recep-
tor-negative, compared with 41 (40.2%) of the other 102
patients. It should be noted that this isolated tumour had a very
low level of CCND1 overexpression (NCCND1=3.3).
Neither CCND1 ampliﬁcation nor CCND1 overexpression with-
out ampliﬁcation was signiﬁcantly linked to menopausal status or
standard prognostic factors such as macroscopic tumour size,
histopathological grade and lymph-node or progesterone receptor
status.
Univariate analysis (log-rank test) showed that relapse-free
survival (RFS) was linked to CCND1 status (P=0.011; Figure 1).
The RFS of the 15 patients with CCND1-ampliﬁed tumours (5-year
RFS 63.0% (36.6–89.4); RR=0.37 (0.15–0.87)) and of the 32
patients with CCND1-unampliﬁed-overexpressed tumours (5-year
RFS 93.8% (85.4–100); RR=1.8 (0.7–4.0)) were respectively short-
er and longer than the RFS of the 87 patients without CCND1
alterations (5-year RFS 80.7% (72.2–89.2); RR=1). The prognostic
signiﬁcance of CCND1 mRNA and DNA status persisted for
lymph-node-negative (P=0.022) but not for lymph-node-positive
patients (P=0.13). Using a Cox proportional hazards model, we
also assessed the prognostic value, for RFS, of parameters that were
signiﬁcant in univariate analysis, i.e. lymph-node status (Table 1)
and CCND1-unampliﬁed-overexpression and CCND1-ampliﬁcation
status (Figure 1). The prognostic signiﬁcance of lymph-node and
CCND1-unampliﬁed-overexpression status only persisted in Cox
multivariate regression analysis (Table 5). The adjusted relative risk
associated with these two parameters, taking into account meno-
pausal status, macroscopic tumour size, histological grade and
steroid receptor status, did not change their prognostic signiﬁcance
for RFS (data not shown).
Relationship between CCND1 mRNA and DNA status and
MYC, ERBB2 and RB1 expression status
Because alterations in any component in the cell cycle regulatory p16/
CCND1/RB1 pathway may have similar oncogenic effects, we studied
the relationship between abnormalities of the CCND1 gene and
altered expression of the RB1 gene, which had already been tested
at the mRNA level (Bie `che and Lidereau, 2000). We observed no
correlation (or a negative correlation) between CCND1 mRNA
and/or DNA alterations and RB1 underexpression (Table 4).
We also observed no link between CCND1 gene abnormalities
and altered mRNA expression of the MYC and ERBB2 genes (Table
4).
DISCUSSION
The aim of this study was to assess the prognostic signiﬁcance of
CCND1 status at both the RNA level (to identify overexpression)
and the DNA level (to identify gene ampliﬁcation) in 134 unilateral
invasive primary breast tumours with a known long-term outcome.
The frequencies of CCND1 ampliﬁcation (11.2%) and overexpres-
sion (33.6%) are in agreement with those previously reported in
the literature (Ali et al, 1989; Borg et al, 1991; Schuuring et al,
1992; Henry et al, 1993; McIntosh et al, 1995; Gillett et al, 1996;
Barbareschi et al, 1997; Jares et al, 1997; Nielsen et al, 1997; Kenny
et al, 1999). Joint analysis of the CCND1 gene at both the mRNA
and DNA levels showed that patients with a good outcome had
CCND1-unampliﬁed-overexpressed tumours while those with a
poor outcome had CCND1-ampliﬁed tumours. Our results conﬁrm
the poor outcome associated with CCND1 ampliﬁcation (Ali et al,
1989; Borg et al, 1991; Schuuring et al, 1992; Henry et al, 1993).
More interestingly, they suggest that CCND1 ampliﬁcation status
should be taken into account when studying the prognostic signif-
icance of CCND1 overexpression. Indeed, the good outcome of
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Table 3 NCCND1 value and ER status in the 15 CCND1-ampliﬁed tumours
Tumour NCCND1 value
a ER status
b
CCND1739 13.6 +
CCND0089 11.2 +
CCND0150 23.7 +
CCND0179 11.4 +
CCND1279 16.5 +
CCND0383 22.2 +
CCND0248 9.6 +
CCND1211 20.4 +
CCND1229 43.7 +
CCND1148 7.6 +
CCND1147 17.8 +
CCND1209 17.2 7
CCND0295 2.7 7
CCND0505 1.6 7
CCND1244 0.6 7
aOverexpression of CCND1 gene when NCCND143;
bER status, as determined by
biochemical method, were conﬁrmed by ERa real-time quantitative
RT–PCR assay to avoid a possible discrepancy due to tumour heterogeneity.
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CCND1 ampliﬁcation. This may explain why some authors have
linked CCND1 overexpression to good outcome (Gillett et al,
1996; Nielsen et al, 1997), while others to poor outcome (McIntosh
et al, 1995; Kenny et al, 1999).
These data on the CCND1 gene status obtained at both the RNA
and DNA levels shed light on several important questions.
The mechanisms underlying CCND1 overexpression in
unampliﬁed tumours
These data conﬁrm our previous report from a small series of
breast tumours (Spyratos et al, 2000) where CCND1 overexpression
is strongly linked to oestrogen receptor positivity. However, is
CCND1 overexpression a cause or a consequence of transcriptional
activation of oestrogen receptors in breast tumour cells? Previously
reported in vitro data suggest that CCND1 overexpression is depen-
dent on the presence of oestrogen and oestrogen receptors, and
that anti-oestrogens inhibit cyclin D1 expression in breast cancer
cells (Sutherland et al, 1997). However, no oestrogen response
element (ERE) has been identiﬁed in the CCND1 promoter.
Sabbah et al (1999) recently suggested a mechanism by which ER
regulates CCND1 gene transcription through a cyclic AMP
response element (CRE). Alternatively, there is increasing evidence
that cyclin D1 forms a direct complex with the oestrogen receptor
and can regulate this transcriptional activity without the need for
oestrogen (Neuman et al, 1997; Zwijsen et al, 1997; McMahon et
al, 1999). Zwijsen et al (1997) observed direct physical binding
of cyclin D1 to the hormone-binding domain of the oestrogen
receptor, resulting in increased binding of the receptor to oestrogen
response-element sequences and upregulating oestrogen receptor-
mediated transcription. Activation of the oestrogen receptor by
cyclin D1 is independent of complex formation to a CDK partner
but necessitates the recruitment of p300/CREB-binding protein-
associated protein (P/CAF) and steroid receptor coactivator-1
(SRC-1), and is not inhibited by anti-oestrogens. Wilcken et al
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Table 4 Relationship between CCND1 mRNA and DNA status and standard clinicopathological and biological factors
Total CCND1-normal CCND1-unampliﬁed- CCND1-
population (%) tumour overexpressed tumour ampliﬁed tumour P value
a
Total 134 (100.0) 87 (64.9)
b 32 (23.9) 15 (11.2)
Age NS
450 years 41 (30.6) 25 (28.7) 12 (37.5) 4 (26.7)
450 years 93 (69.4) 62 (71.3) 20 (62.5) 11 (73.3)
Menopausal NS
Premenopausal 47 (35.1) 31 (35.6) 13 (40.6) 3 (20.0)
Post-menopausal 87 (64.9) 56 (64.4) 19 (59.4) 12 (80.0)
Histological grade
c,d NS
I+II 78 (62.4) 48 (58.5) 20 (71.4) 10 (66.7)
III 47 (37.6) 34 (41.5) 8 (28.6) 5 (33.3)
Lymph node status NS
Node-negative 50 (37.3) 34 (39.1) 12 (37.5) 4 (26.7)
Node-positive 84 (62.7) 53 (60.9) 20 (62.5) 11 (73.3)
ER status 0.0003
+(510 fm per mg) 92 (68.7) 50 (57.5) 31 (96.9) 11 (73.3)
7(510 fm per mg) 42 (31.3) 37 (42.5) 1 (3.1) 4 (26.7)
PR status NS
+(510 fm per mg) 79 (59.0) 50 (57.5) 22 (68.8) 7 (46.7)
7(510 fm per mg) 55 (41.0) 37 (42.5) 10 (31.2) 8 (53.3)
Macroscopic tumour size
e NS
430 mm 93 (73.2) 61 (72.6) 20 (71.4) 12 (80.0)
430 mm 34 (26.7) 23 (27.4) 8 (28.6) 3 (20.0)
RNA MYC status
f NS
Overexpressed 29 (21.6) 20 (23.0) 7 (21.9) 2 (13.3)
Normal 105 (78.4) 67 (77.0) 25 (78.1) 13 (86.7)
RNA ERB2 status
g NS
Overexpressed 23 (17.4) 15 (17.2) 6 (18.8) 2 (13.3)
Normal 111 (82.8) 72 (82.8) 26 (81.2) 13 (86.7)
RNA RB1 status
h,i NS
Underexpressed 27 (21.4) 17 (20.5) 6 (20.0) 4 (30.8)
Normal 99 (78.6) 66 (79.5) 24 (80.0) 9 (69.2)
aChi-square test;
bNumber of patients;
cScarff Bloom Richardson classiﬁcation;
dInformation available for 125 patients;
eInformation available for 127 patients;
fBie `che et al
(1999a);
gBie `che et al (1999b);
hBie `che et al, in preparation;
iInformation available for 126 patients.
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overcome in both T-47D and MCF7 cells when cyclin D1 expres-
sion was ectopically induced. The inﬂuence of cyclin D1 status
on the response to oestrogen and anti-oestrogens such as the
tamoxifen warrants further study.
The good outcome of patients with CCND1 overexpressing
tumours
One simple explanation is that CCND1 overexpression is associated
with well-differentiated, oestrogen receptor-positive tumours
(which are known to have a more favourable prognosis and a
respond better to anti-oestrogen therapy. Alternatively, it may be
due to more rapid cell proliferation and, thus, greater chemosensi-
tivity. The possible relation between CCND1 overexpression and
the response to chemotherapy could not be studied in this retro-
spective series of unselected patients because the treatments used
after surgery were highly variable. To test this hypothesis, it will
be necessary to conduct a prospective randomized clinical study
to show that CCND1 overexpression do inﬂuence outcome only
in patients who received chemotherapy as compared to untreated
patients.
The possible involvement of the CCND1 gene in 11q13
amplicon selection and the poorer outcome of patients with
11q13-ampliﬁed tumours
The more plausible explanation is that CCND1 has a true role of
oncogene and it is a more important gene as a driving force for
11q13 ampliﬁcation. Ampliﬁcation at 11q13 leads to higher
CCND1 expression, resulting in more rapid proliferation of epithe-
lial breast tumours and, thus, in poorer outcome.
However, three of the 15 11q13-ampliﬁed tumours were exam-
ined had not CCND1 overexpression (Table 3). Similar breast
tumours have been observed by several other authors (Gillett et
al, 1994; Barbareschi et al, 1997). Moreover, we previously showed
that CCND1 mRNA overexpression is not related to a proliferative
marker, the S-phase fraction, measured by ﬂow cytometry (Spyra-
tos et al, 2000).
Conversely, the ampliﬁcation unit on chromosome 11q13 may
encompass other gene(s) that could be the major 11q13 amplicon
selector and whose overexpression might contribute to poor clini-
cal outcome. One candidate is the oncogene EMS1, which is
located approximately 800 kb telomeric to CCND1 and encodes
an cytoskeletal actin-binding protein. It is ampliﬁed and over-
expressed independently of CCND1 and oestrogen receptor expres-
sion, and, in contrast to cyclin D1, is not regulated by oestrogen
(Hui et al, 1998). Thus, CCND1 overexpression could be due
exclusively to the presence of oestrogen receptors, and the higher
CCND1 overexpression observed in ampliﬁed tumours than in
overexpressed-unampliﬁed tumours could be due to a simple gene
dosage effect. In agreement with this hypothesis, the three 11q13-
ampliﬁed tumours with CCND1 normal expression were oestrogen
receptor-negative (Table 3). However, it should be noted that we
also observed one oestrogen receptor-negative tumour with
CCND1 overexpression and ampliﬁcation (Tumour CCND1209;
Table 3).
Finally, 11q13 ampliﬁcation may simply reﬂect genomic instabil-
ity in breast tumours. Coquelle et al (1998) showed a key role of
hypoxia in inducing breaks at fragile sites and initiating intrachro-
mosomal ampliﬁcation. Such fragile sites (FRA11A and FRA11F)
are located on each side (centromeric and telomeric) of the
11q13 amplicon.
In conclusion, we observed a major link between CCND1
mRNA status and ER status, conﬁrming a role for the CCND1 gene
as an ER-responsive gene or ER-coactivator gene in breast cancer.
CCND1 ampliﬁcation might simply be an additional mechanism
contributing to high levels of CCND1 overexpression observed in
oestrogen receptor-positive tumours, through a simple gene dosage
effect. These ﬁndings, together with the observation of several
oestrogen receptor-negative tumours with 11q13 ampliﬁcation
but no CCDN1 overexpression, challenge CCND1 gene as the main
11q13 amplicon selector.
CCND1 may serve as a molecular marker for predicting
hormone responsiveness in breast cancer, as hypothesis currently
being tested in a large and homogeneous clinical study.
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